argenx: Summary

argenx

Pharmaceutical, Biotechnology, Immunology, Autoimmune Diseases

To improve the lives of patients suffering from severe autoimmune diseases through innovative immunology solutions.

argenx is a global immunology company focused on developing innovative therapies for severe autoimmune diseases and cancer. The company leverages collaboration and scientific advancements to create life-changing immunology solutions.

Innovative antibody engineering; Collaboration with academic partners; Focus on severe autoimmune diseases; Proprietary portfolio of first-in-class product candidates

Primary scenarios include treatment for severe autoimmune diseases such as generalized myasthenia gravis and CIDP, as well as ongoing clinical trials for other conditions.

Strong focus on patient-centric solutions; Robust pipeline of first-in-class therapies; Established partnerships with leading academic institutions

Key strengths include a commitment to innovation, a strong pipeline of product candidates, and a collaborative ecosystem that enhances research and development.

argenx positions itself as a leader in immunology innovation, dedicated to transforming patient care through advanced therapeutic solutions.

Target users include patients suffering from severe autoimmune diseases, healthcare professionals, and researchers in the field of immunology.

Learn more

• Immunology

• Autoimmune Diseases

• Therapeutics

• Innovation

Reaching Patients Through Immunology Innovation

Innovative, compassionate, collaborative

argenx stands out in the market by combining cutting-edge antibody engineering with a collaborative approach that integrates insights from both scientists and patients.

The brand identity of argenx is centered around collaboration, innovation, and a deep commitment to improving patient outcomes.

2008-01-01

• Tim Van Hauwermeiren